Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.13% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2401
Luxfer Holdings
LXFR
$457M
| $1.35M | ﹤0.01% |
95,399
-78,500
| -45% | -$1.08M |
|
2402
Cardiff Oncology
CRDF
$76.6M
| $1.35M | ﹤0.01% |
268,800
+129,091
| +92% | +$264K |
|
2403
Security National Financial
SNFCA
$241M
| $1.34M | ﹤0.01% |
273,927
+17,642
| +7% | +$76.3K |
|
2404
NI Holdings
NODK
$314M
| $1.34M | ﹤0.01% |
90,701
+15,900
| +21% | +$216K |
|
2405
iShares MSCI Hong Kong ETF
EWH
$1.2B
| $1.34M | ﹤0.01% |
+62,600
| New | +$1.32M |
|
2406
Perma-Fix Environmental Services
PESI
$365M
| $1.34M | ﹤0.01% |
209,418
+23,678
| +13% | +$137K |
|
2407
MannKind Corp
MNKD
$1.23B
| $1.33M | ﹤0.01% |
+762,715
| New | +$1.07M |
|
|
ATXI
2408
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
| $1.33M | ﹤0.01% |
110
+51
| +86% | +$575K |
|
|
ALYA
2409
DELISTED
Alithya Group Inc Class A Subordinate Voting Shares
ALYA
| $1.32M | ﹤0.01% |
802,961
+10,900
| +1% | +$19.1K |
|
2410
Moleculin Biotech
MBRX
$4.4M
| $1.32M | ﹤0.01% |
608
+46
| +8% | +$109K |
|
|
HHR
2411
DELISTED
HeadHunter Group PLC American Depositary Shares
HHR
| $1.32M | ﹤0.01% |
56,600
+8,778
| +18% | +$164K |
|
|
JCTC
2412
Jewett-Cameron Trading
JCTC
$10.2M
| $1.32M | ﹤0.01% |
178,975
-6,500
| -4% | -$39.6K |
|
2413
China Automotive Systems
CAAS
$141M
| $1.32M | ﹤0.01% |
455,835
-1,425
| -0.3% | -$2.9K |
|
2414
Everspin Technologies
MRAM
$448M
| $1.31M | ﹤0.01% |
187,006
-75,219
| -29% | -$370K |
|
|
VRS
2415
DELISTED
Verso Corporation
VRS
| $1.31M | ﹤0.01% |
109,700
+73,600
| +204% | +$964K |
|
2416
Marcus Corp
MCS
$916M
| $1.31M | ﹤0.01% |
98,800
+59,400
| +151% | +$796K |
|
2417
Mistras Group
MG
$579M
| $1.31M | ﹤0.01% |
331,940
-270,900
| -45% | -$1.12M |
|
|
OBSV
2418
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $1.3M | ﹤0.01% |
221,500
+96,200
| +77% | +$363K |
|
2419
iShares US Medical Devices ETF
IHI
$3.47B
| $1.3M | ﹤0.01% |
+29,400
| New | +$1.26M |
|
2420
PCB Bancorp
PCB
$399M
| $1.3M | ﹤0.01% |
125,932
+9,100
| +8% | +$82.4K |
|
2421
Scholar Rock
SRRK
$6.41B
| $1.29M | ﹤0.01% |
+70,800
| New | +$1.21M |
|
|
FENG
2422
Phoenix New Media
FENG
$18.1M
| $1.28M | ﹤0.01% |
144,565
+21,200
| +17% | +$176K |
|
|
HT
2423
DELISTED
Hersha Hospitality Trust Priority Class A Common Shares of Beneficial Interest
HT
| $1.28M | ﹤0.01% |
+222,460
| New | +$1.19M |
|
2424
Universal Insurance Holdings
UVE
$1.19B
| $1.28M | ﹤0.01% |
72,000
+12,500
| +21% | +$221K |
|
2425
FerroAtlántica
GSM
$815M
| $1.28M | ﹤0.01% |
2,572,985
-1,800
| -0.1% | -$1.07K |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.